StemCells, Inc.

StemCells, Inc. is a leading biotechnology research company dedicated to the clinical development of its innovative HuCNS-SC® platform technology, which utilizes purified human neural stem cells. StemCells, Inc. focuses on creating potential treatments for neurological and retinal disorders. The company is located at 7707 Gateway Blvd., Suite 140, Newark, California 94560, US, and also has a location at Minerva Building 250, Babraham Research Campus, Cambridge, CB22 3AT, GB.

StemCells, Inc. has demonstrated promising results in its clinical trials, including measurable gains in sensory modalities and segments in thoracic spinal cord injury (SCI) patients. The Pathway™ Study, a Phase II proof-of-concept trial in cervical SCI, is actively enrolling, and the Radiant™ Study, a Phase II proof-of-concept trial in GA-AMD, is also underway. Furthermore, StemCells, Inc. has shown preliminary evidence of donor-derived myelination in a Phase I clinical trial for Pelizaeus-Merzbacher disease (PMD).

With a commitment to advancing medical science and improving patient outcomes, StemCells, Inc. continues to push the boundaries of biotechnology research. We invite the manager of StemCells, Inc. to create a customized and exclusive company showcase and product listing on our platform to further enhance your company's visibility and commercial development.